M3, Inc (MTHRF) Fair Value & Analysis
Healthcare · US · Market cap $5.7B
M3, Inc
MTHRF · US
Fair value as of: Jul 18, 2026
From 26 valuation models · updated 5 days ago
Price vs Fair Value (12 months)
12‑month range $8.24 – $98.61 · fair‑value band $7.57 – $12.62 · the $8.55 price screens below the $10.10 fair value. As of Jul 18, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
M3, Inc (MTHRF) currently trades at $8.55, while our model-based Fair Value estimate is $10.10, implying the stock looks roughly 18.1% undervalued today. We read business quality at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, M3, Inc generated revenue of $351B at a net margin of 14.0%. Revenue grew 9.6% year over year. It earns a return on equity of 12.6%. The balance sheet holds a net cash position of $153B. Fundamentals as of Jul 18, 2026
Our scenario range runs from $7.57 (bear case) to $12.62 (bull case); at $8.55, the current price sits within that range. The share trades about 44% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -31% fair-value upside, at 18%, MTHRF screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 18, 2026. TTM = trailing twelve months.
About the company
M3, Inc. provides medical-related services to physicians and other healthcare professionals through the internet. It operates m3.com, a members-only website for providing information, tools, and services for medical professionals; MR-kun which delivers the latest medical information for daily medical practice; QOL-kun, a marketing support service that provides selected information useful for doctors; m3.com CAREER, a physician recruitment and career change support site; and Drug Carrier, a job information site for pharmacists. The company also provides online lectures; clinical trial; research targeting domestic medical professionals; medical-related self-planned data and research reports; global health professional research; survey panel provision services; and m3.com opening and management services. In addition, it offers AskDoctors, where registered doctors answer questions about health and illness from the public; MDLinx for medical professionals in the United States; and …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
M3, Inc reported revenue of $354B in FY2026 versus $208B in FY2022, a compound +14.2%/yr. Reported net income was $49.4B in FY2026, compounding −6.2%/yr from FY2022.
Is MTHRF fairly valued? → Check now
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $172.61 | $104.16 | -40% |
| Pro Medicus Limited PME | A$165.64 | A$28.02 | -83% |
| BrightSpring Health Services, Inc BTSG | $60.59 | $23.87 | -61% |
| HealthEquity, Inc HQY | $84.61 | $79.57 | -6% |
| Hinge Health, Inc HNGE | $62.06 | $78.43 | +26% |
| 10x Genomics, Inc TXG | $32.94 | $22.67 | -31% |
| Waystar Holding WAY | $18.80 | $14.86 | -21% |
| Ping An Healthcare and Technology Company PANHF | $0.9000 | $0.5700 | -37% |
| XtalPi Holdings 2228 | HK$7.48 | HK$1.03 | -86% |
| Doximity, Inc DOCS | $20.24 | $29.27 | +45% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is M3, Inc (MTHRF) undervalued?
What is the fair value of MTHRF?
What is the quality score of MTHRF?
What is the revenue of M3, Inc (MTHRF)?
What is the net profit margin of MTHRF?
Does M3, Inc pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full M3, Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.